Key result
Silencing AKAP2 expression or disrupting its interaction with F-actin inhibits the ERK-WAVE2 signaling axis and impairs cardiac myofibroblast migration.
Why the study?
Although the enhanced migratory capacity of cardiac myofibroblasts contributes to cardiac fibrosis, the molecular mechanisms controlling their motile function remain poorly defined.
AKAP2 acts as a molecular scaffold for ERK1 activation, driving cardiac myofibroblast migration and potentially contributing to cardiac fibrosis.
Cardiac fibrosis is a major cause of dysfunctions and arrhythmias in failing hearts. At the cellular level fibrosis is mediated by cardiac myofibroblasts, which display an increased migratory capacity and secrete large amounts of extracellular matrix. These properties allow myofibroblasts to invade, remodel and stiffen the myocardium and eventually alter cardiac function. While the enhanced ability of cardiac myofibroblasts to migrate has been proposed to contribute to the initiation of the fibrotic process, the molecular mechanisms controlling their motile function have been poorly defined. In this context, our current findings indicate that A-kinase anchoring protein 2 (AKAP2) associates with actin at the leading edge of migrating cardiac myofibroblasts. Proteomic analysis of the AKAP2 interactome revealed that this anchoring protein assembles a signaling complex composed of the extracellular regulated kinase 1 (ERK1) and its upstream activator Grb2 that mediates the activation of ERK in cardiac myofibroblasts. Silencing AKAP2 expression results in a significant reduction in the phosphorylation of ERK1 and its downstream effector WAVE2, a protein involved in actin polymerization, and impairs the ability of cardiac myofibroblasts to migrate. Importantly, disruption of the interaction between AKAP2 and F-actin using cell-permeant competitor peptides, inhibits the activation of the ERK-WAVE2 signaling axis, resulting in a reduction of the translocation of Arp2 to the leading-edge membrane and in inhibition of cardiac myofibroblast migration. Collectively, these findings suggest that AKAP2 functions as an F-actin bound molecular scaffold mediating the activation of an ERK1-dependent promigratory transduction pathway in cardiac myofibroblasts.
No takes yet. Share an insight, caveat, or question.
Delaunay et al. (2024) studied Cardiac fibrosis. Silencing AKAP2 expression or disrupting AKAP2/F-actin interaction was evaluated on Cardiac myofibroblast migration and ERK1/WAVE2 phosphorylation. Silencing AKAP2 expression or disrupting its interaction with F-actin inhibits the ERK-WAVE2 signaling axis and impairs cardiac myofibroblast migration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: